{
    "clinical_study": {
        "@rank": "134710", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Determine whether parenteral relaxin improves skin tightness, Raynaud's\n      phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic\n      sclerosis (scleroderma).\n\n      II.  Determine whether relaxin decreases collagen production by fibroblasts in vivo and\n      cultured from skin biopsies."
        }, 
        "brief_title": "Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis", 
        "completion_date": "December 1997", 
        "condition": "Systemic Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Scleroderma, Systemic", 
                "Scleroderma, Diffuse", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a compassionate use study. The patient is treated with\n      subcutaneous injections of recombinant relaxin for approximately 12 months.  If clinically\n      indicated, therapy may be extended."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Progressive systemic sclerosis (scleroderma)\n\n          -  No pregnant or nursing women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "1", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004380", 
            "org_study_id": "199/12015", 
            "secondary_id": "SUMC-37488"
        }, 
        "intervention": {
            "intervention_name": "relaxin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Methocarbamol"
        }, 
        "keyword": [
            "arthritis & connective tissue diseases", 
            "rare disease", 
            "systemic sclerosis"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "G. Scott Herron", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004380"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Stanford University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 1991", 
        "study_design": "Allocation: Non-Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2004"
    }, 
    "geocoordinates": {}
}